DA-0157

Overview

DA-0157 is the orally active inhibitor for EGFR and ALK that overcomes drug-resistant mutations of EGFR C797S and ALK in NSCLC) cells. DA-0157 inhibits the proliferation of Ba/F3-EGFR Del19/T790M/C797S ( IC 50 = 6.9 nM), Ba/F3-EGFR WT ( IC 50 = 0.83 μM), Ba/F3-EML4-ALK-L1196M ( IC 50 = 5.5 nM), and Ba/F3-EML4-ALK ( IC 50 = 7.4 nM). DA-0157 inhibits CYP2D6 with IC 50 of 5.26 μM. DA-0157 exhibits antitumor efficacy in mouse models.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Signaling Pathways > EGFR | Products > Signaling Pathways > Anaplastic lymphoma kinase (ALK) | Products > Signaling Pathways > Cytochrome P450

Product Information

• Catalog No.: HY-170928
• CAS No.: 2756978-82-0
• Molecular Formula: C31H43BrN7O2P
• Molecular Weight: 656.60
• Purity: 99.59%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2 mg/mL (3.05 mM); Suspended solution
• Availability: In-stock

Source

Original product source